RecruitingRecruiting
Immune Spatial Features of Guselkumab Cutaneous Response
NCT05858632 · University of California, San Francisco
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
This is a one-arm, open-label study to examine the effect of Guselkumab . Guselkumab is a FDA-approved medication for the treatment of psoriasis. This study will examine how Guselkumab affects immune cells within scalp psoriasis lesions. Ten subjects with moderate to severe scalp psoriasis will be enrolled. Biopsy samples will be collected and undergo molecular profiling to correlate profiles with Guselkumab treatment response.
Eligibility criteria
Inclusion Criteria: possess a PSSI (psoriasis scalp severity index) of ≥12
Exclusion Criteria:
1. taking systemic immunosuppressives in the last 4 weeks
2. pregnancy
3. severe immunodeficiency (either from genetic or infectious causes).
4. tuberculosis or other active serious infection
5. active systemic malignancy.
6. breast-feeding
7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
8. Males who are trying to conceive
\-
Study design
Enrollment target: 10 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2023-07-01
Estimated completion: 2028-06-30
Last updated: 2026-06-04
Interventions
Drug: Guselkumab
Primary outcomes
- • Change in psoriasis scalp severity index score (PSSI) (baseline and 9 months)
Sponsor
University of California, San Francisco · other
With: Janssen Scientific Affairs, LLC
Contacts & investigators
ContactJeffrey Cheng, MD, PhD · contact · rashes@ucsf.edu · 415 575 0524
ContactRaymond Cho, MD,PhD · contact
InvestigatorRaymond Cho, MD, PhD · principal_investigator, University of California, San Francisco
All locations (1)
University of California San FranciscoRecruiting
San Francisco, California, United States